CVE:LBL Lattice Biologics (LBL) Stock Price, News & Analysis C$0.04 0.00 (0.00%) As of 06/3/2021 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Lattice Biologics Stock (CVE:LBL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lattice Biologics alerts:Sign Up Key Stats Today's RangeC$0.04▼C$0.0450-Day RangeC$0.04▼C$0.0452-Week RangeC$0.03▼C$0.13Volume114,000 shsAverage Volume468,022 shsMarket CapitalizationC$5.13 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. It develops novel amniotic fluid-based products, such as AmnioBoost and AmnioBlast. The company also offers traditional, spinal, particulate, soft tissue, dental, membrane and barrier, and demineralized bone matrix allografts. Its products are used in a range of applications, including enhancing fusion in spine surgery and breast reconstruction post mastectomy, promotion of bone regeneration in foot and ankle surgery, promotion of skull healing following neurosurgery, enhancing wound repair in burn victims, hernia repair, and subchondral bone defect repair in knee and other joint surgeries, as well as sports medicine indications, such as anterior and posterior cruciate ligament repair. The company is headquartered in Belgrade, Montana. Read More Receive LBL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lattice Biologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LBL Stock News HeadlinesBest Lattice Alternatives Of 2024September 16, 2024 | forbes.comIVBIY Innovent Biologics, Inc.January 10, 2024 | seekingalpha.com$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold stocks — in past bull markets, these plays delivered gains as high as 5,000% to 9,800%, and Sean has now identified five companies he believes could see explosive moves in the early stages of what may be the biggest gold rally yet. | Weiss Ratings (Ad)AbCellera Biologics GAAP EPS of -$0.14, revenue of $12MMay 7, 2023 | seekingalpha.comADMA Biologics Stock (NASDAQ:ADMA), Analyst Ratings, Price Targets, PredictionsMarch 28, 2023 | benzinga.comLattice Biologics Ltd (LBLh)March 2, 2023 | investing.comLattice Announces Lattice Connect Partner Ecosystem to Help Organizations Maximize People SuccessSeptember 23, 2022 | markets.businessinsider.comLattice Semiconductor Corp LSCC Stock QuoteSeptember 9, 2022 | morningstar.comMSee More Headlines LBL Stock Analysis - Frequently Asked Questions How have LBL shares performed this year? Lattice Biologics' stock was trading at C$0.04 on January 1st, 2025. Since then, LBL stock has increased by 0.0% and is now trading at C$0.04. How do I buy shares of Lattice Biologics? Shares of LBL stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Lattice Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lattice Biologics investors own include 50904 (GRC.V) (GRC), Air Canada (AC), Allied Gaming & Entertainment (AGAE), Avino Silver & Gold Mines (ASM), Academy Sports and Outdoors (ASO), Antibe Therapeutics (ATE) and BioCryst Pharmaceuticals (BCRX). Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolCVE:LBL CIKN/A Webwww.latticebiologics.com Phone+1-604-2356701FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.02 Quick Ratio0.02 Sales & Book Value Annual SalesC$1.56 million Price / Sales3.29 Cash FlowN/A Price / Cash FlowN/A Book ValueC$0.00 per share Price / Book40.00Miscellaneous Outstanding Shares128,218,000Free FloatN/AMarket CapC$5.13 million OptionableNot Optionable BetaN/A The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (CVE:LBL) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored“Godfather of AI’s” dire warningAI pioneer Geoffrey Hinton warns the technology could create massive unemployment and widen inequality, but Po...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lattice Biologics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lattice Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.